Correlation Engine 2.0
Clear Search sequence regions

Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and differentiation. Consequently, genetic alterations of TKRs may lead to tumorigenesis and, therefore, cancer development. The discovery and improvement of tyrosine kinase inhibitors (TKI) against TKRs have entailed an important step in the knowledge-expansion of tumor physiopathology as well as an improvement in the cancer treatment based on molecular alterations over many tumor types. The purpose of this review is to provide a comprehensive review of the different families of TKRs and their role in the expansion of tumor cells and how TKIs can stop these pathways to tumorigenesis, in combination or not with other therapies. The increasing growth of this landscape is driving us to strengthen the development of precision oncology with clinical trials based on molecular-based therapy over a histology-based one, with promising preliminary results.


Jorge Esteban-Villarrubia, Juan José Soto-Castillo, Javier Pozas, María San Román-Gil, Inmaculada Orejana-Martín, Javier Torres-Jiménez, Alfredo Carrato, Teresa Alonso-Gordoa, Javier Molina-Cerrillo. Tyrosine Kinase Receptors in Oncology. International journal of molecular sciences. 2020 Nov 12;21(22)

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 33198314

View Full Text